Skip to main content
. Author manuscript; available in PMC: 2015 Feb 18.
Published in final edited form as: J Clin Exp Neuropsychol. 2002 Sep;24(6):765–780. doi: 10.1076/jcen.24.6.765.8402

Table 3.

Demographic, Historical, and Clinical Data for Each Neurocognitive Cluster of Schizophrenia.

Neurocognitive cluster
Cluster I Cluster II Cluster III Cluster IV

Variable n = 15 n = 76 n = 41 n = 19
Sex, M/F 9/6 44/32 23/18 12/7
Age 37.00±12.58 31.39±9.69 31.44±10.48 30.86±9.96
Education 11.20±1.21 13.97±2.10 12.56±1.70 12.00±2.16
Parental education 10.50±1.52 13.15±2.93 12.58±2.57 12.17±2.72
Age of onseta 23.75±5.51 24.60±6.74 23.67±6.94 19.50±4.97
Illness duration 8.04±4.33 6.43±5.93 7.94±9.12 10.23±7.88
No. of hospitalizations 4.27±6.40 2.50±5.83 1.65±2.55 3.50±4.82
BPRS total 44.80±10.35 44.00±9.46 42.78±12.15 44.89±12.19
SANS total 52.93±26.85 35.77±20.99 45.29±27.81 46.11±27.46
SAPS total 43.80±24.87 37.67±19.99 32.27±19.43 39.58±28.61
Negative – Affect 2.27±1.10 1.96±1.22 2.34±1.41 2.37±1.61
Negative – Alogia 2.73±1.33 1.21±1.36 2.05±1.45 2.42±1.46
Negative – Anhedonia 3.13±1.46 2.79±1.35 2.66±1.37 2.63±1.57
Negative – Avolition 3.07±1.33 2.03±1.40 2.10±1.56 2.21±1.32
Negative – Attention 2.20±1.57 0.95±1.20 1.83±1.30 1.74±1.63
Positive – Hallucination 2.80±1.66 2.21±1.52 1.88±1.60 2.47±1.74
Positive – Delusionb 3.07±.96 3.19±1.14 2.41±1.20 2.58±1.35
Positive – Bizarre 1.40±1.30 0.89±1.18 1.15±1.28 1.68±1.29
Positive – Thought Dis. 2.27±1.83 1.41±1.32 2.00±1.38 1.68±1.38
Negative composite 2.24±1.13 1.67±.94 2.00±1.22 2.06±1.23
Dis./Thgt composite 1.60±1.16 1.12±.77 1.42±.79 1.43±.99
Par-Host composite 2.70±1.28 2.97±1.18 2.52±1.33 2.22±1.08
Schneiderian composite 1.74±1.10 1.46±1.12 1.05±.91 1.68±1.28

Note. Cluster I: Severe and Profound Global Dysfunction.

Cluster II: Near Normative Performance with Mild Dysfunction in Verbal Memory.

Cluster III: Moderate-severe with more Prominent Executive than Memory Dysfunction.

Cluster IV: Moderate-severe with more Prominent Memory than Executive Dysfunction.

a

II > IV.

b

II > III.

HHS Vulnerability Disclosure